MARKET NEWS

VIVEbiotech Continues Expansion of its Lentiviral Vector Manufacturing Capabilities to Address the Viral Vector Bottleneck
EyePoint Pharmaceuticals & OcuMension Therapeutics Announce Approval of NDA  for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Acer Therapeutics & Relief Therapeutics Announce Update on US FDA Review of NDA
Hepion Pharmaceuticals Receives Orphan Drug Status Designation for the Treatment of Hepatocellular Carcinoma
VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease

  FEATURED EDITORIAL

  COMPANY PROFILE

Serán Bioscience is a science-first CDMO, recognized as a leader in materials science, formulation development, and pharmaceutical manufacturing. We utilize a foundation of physical and chemical science to design robust formulations and engineered solutions. Our science, quality systems, regulatory expertise, and customer service are second to none. Your drug is your future, and you need a CMC partner that’s as committed to your success as you are. Click here for more.


Video Spotlight: MilliporeSigma – Emprove® Excipients for Full Supply Chain Transparency

  EXCLUSIVE ONLINE CONTENT

Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer

Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer

Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation recently announced the creation of a subgroup of researchers to focus on cancer treatment. ….

Valneva & Pfizer Enter Equity Subscription Agreement & Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate

Valneva & Pfizer Enter Equity Subscription Agreement & Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate

Valneva SE and Pfizer Inc. recently announced they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15…..

Mitsubishi Gas Chemical & BD Have Signed LOI to Discuss Partnership Agreement to Explore New Ways to Advance Biologic Drug Delivery

Mitsubishi Gas Chemical & BD Have Signed LOI to Discuss Partnership Agreement to Explore New Ways to Advance Biologic Drug Delivery

Mitsubishi Gas Chemical Company, Inc. and BD recently announced they have entered into an agreement to investigate further development of OXYCAPT – an innovation from MGC that integrates….

Kindeva Announces Collaboration With Synopsys

Kindeva Announces Collaboration With Synopsys

Kindeva Drug Delivery recently announced a collaboration with Synopsys, Inc. involving the implementation of Synopsys Simpleware automated software solutions to assist in creating….

  WHITEPAPERS & WEBINARS

WEBINAR - Understanding Patch Composition for Effective Transdermal Delivery

WEBINAR - Understanding Patch Composition for Effective Transdermal Delivery

As the advantages of transdermal drug delivery grow, the global market for transdermal patches also is growing. Join DuPont™ Liveo™ Healthcare Solutions and Gattefossé Pharmaceuticals for a complimentary one-hour webinar to explore the current….

WEBINAR - ILC Dover: Handling Potent Products in a Sterile Environment

WEBINAR - ILC Dover: Handling Potent Products in a Sterile Environment

The need for flexible solutions for potent product handling is increasing. We’ll discuss the proven benefits of aseptic isolator systems in sterile environments and take a look at real feedback from real customers of ours in an upcoming webinar on Tuesday, November 16th at 11:00 AM EST.

Bespak by Recipharm Webinar: Learn How To Overcome Viscous Formulation Challenges For Parenteral Delivery

Bespak by Recipharm Webinar: Learn How To Overcome Viscous Formulation Challenges For Parenteral Delivery

There have been many challenges holding back widespread adoption of self-administered injectable formulations. One of the most pressing is the need to develop an auto-injector with a fine enough needle for….

  WHITEPAPERS & WEBINARS

WHITEPAPER - The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation

WHITEPAPER - The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation

This white paper evaluates the viscosity-reducing capacities of excipients and excipient combinations. It shows the over-additive effect of using two excipients together and addresses how excipients’ viscosity-reducing ability depends on pH. The results show the effect of protein viscosity on …

WHITEPAPER - Protecting Workers and the Environment: Facilities and Processes Key to Safely Making Highly Potent Drug Products

WHITEPAPER - Protecting Workers and the Environment: Facilities and Processes Key to Safely Making Highly Potent Drug Products

Highly potent APIs (HPAPI) are rapidly growing in the pharmaceutical industry. Manufacturing solid oral dosage forms (SOD) containing HPAPIs requires specific knowledge, skills, and precision without compromising environmental or worker safety.

Enteris BioPharma’s HPAPI manufacturing facility was custom-built with comprehensive …

WHITE PAPER: Bring Quality OINDPs to Market Faster Than Ever Before | Proveris Scientific

WHITE PAPER: Bring Quality OINDPs to Market Faster Than Ever Before | Proveris Scientific

The Proveris by Design™ process offers a formalized approach to product development, all the while automating in vitro testing, and streamlining troubleshooting. It is an indispensable tool for successfully developing nasal spray and inhalation drug products as well as critical …

WHITEPAPER: Optimizing Oral Drug Delivery Using Zydis® Orally Disintegrating Tablet Technology to Address Patient Challenges

WHITEPAPER: Optimizing Oral Drug Delivery Using Zydis® Orally Disintegrating Tablet Technology to Address Patient Challenges

Many patients prefer conventional tablets for the administration of medications, but some geriatric and pediatric patients and those with altered mental status and physical impairments find swallowing tablets to be difficult. Orally disintegrating tablets (ODTs), which dissolve completely without chewing …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

June 29 – Prefilled Syringes
July 6 – Inhalation Delivery